Sign in or create an account to add this stock to your watchlist.
About Intercept Pharmaceuticals (NASDAQ:ICPT)
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis (PBC). In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist, a second dedicated bile acid receptor that has completed a Phase 1 clinical trial; and INT-777, an orally administered TGR5 agonist, which completed preclinical studies for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ICPT
CUSIP45845P10
Phone646-747-1000
Debt
Debt-to-Equity Ratio-6.88
Current Ratio4.58
Quick Ratio4.58
Price-To-Earnings
Trailing P/E Ratio-4.94
Forward P/E Ratio-6.22
P/E GrowthN/A
Sales & Book Value
Annual Sales$130.96 million
Price / Sales16.05
Cash FlowN/A
Price / CashN/A
Book Value($1.77) per share
Price / Book-40.15
Profitability
EPS (Most Recent Fiscal Year)($14.38)
Net Income$-360,360,000.00
Net Margins-241.33%
Return on Equity-573.64%
Return on Assets-68.54%
Miscellaneous
Employees507
Outstanding Shares29,580,000
Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions
What is Intercept Pharmaceuticals' stock symbol?
Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."
How were Intercept Pharmaceuticals' earnings last quarter?
Intercept Pharmaceuticals (NASDAQ:ICPT) released its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($3.22) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($3.41) by $0.19. The biopharmaceutical company had revenue of $35.96 million for the quarter, compared to analyst estimates of $38.44 million. Intercept Pharmaceuticals had a negative return on equity of 573.64% and a negative net margin of 241.33%. The company's revenue was up 70.9% on a year-over-year basis. During the same quarter last year, the firm posted ($3.61) EPS. View Intercept Pharmaceuticals' Earnings History.
What price target have analysts set for ICPT?
21 Wall Street analysts have issued 12 month price objectives for Intercept Pharmaceuticals' stock. Their forecasts range from $50.00 to $253.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $124.4737 in the next twelve months. View Analyst Ratings for Intercept Pharmaceuticals.
What are Wall Street analysts saying about Intercept Pharmaceuticals stock?
Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, "PBC – Despite headwinds associated with labeling harmonization for Ocaliva and widened gross-to-net impact expected for the earlier portion of the year, scripts for the drug have been reported to have stabilized. We believe efforts towards educating and creating confidence for prescribing physicians may have stemmed the tide and signal the return to revenue growth. While our long-term projections remain conservative (20% at peak), continued execution in the remainder of 2018 could build our confidence and expand opportunity for the shares. That said, we remain cautious on NASH." (5/8/2018)
- 2. According to Zacks Investment Research, "Intercept’s fourth-quarter results missed expectations as sales of Ocaliva declined due to safety issues surrounding the drug. The approval of Ocaliva was a significant boost for Intercept. However, prescription demand has softened following the Dear Health Care Provider letter and the FDA safety communication on Ocaliva. The company also announced an updated label for Ocaliva in the United States, reinforcing appropriate dosing in PBC patients with Child-P Class B or C or decompensated cirrhosis. While the updated label should help the stock turn around, it might be a while before the sales start to recover. First-quarter is expected to be a transitional quarter. Meanwhile, Intercept is evaluating Ocaliva for other indications including NASH and PSC. Given the challenges faced by the drug in recent times, the label expansion of OCA will boost the growth prospects. Shares have underperformed the industry in the last six months." (2/19/2018)
- 3. Needham & Company LLC analysts commented, "Intercept reported $40.9M in WW 3Q17 Ocaliva sales, with $4.1M attributed to one-time accounting adjustment. Excluding adjustment, WW and U.S. Ocaliva sales were $36.8M and $32.5M, respectively, both in-line with our and consensus $36M and $33M ests. Company has completed safety review w/ independent committee and discussions w/ FDA are underway. Changes to U.S. label are expected by early 1Q18. Safety concerns appear to have had modest impact on NRX since FDA letter and we have reduced our ests accordingly. Long-term sales in PBC may be negatively impacted by large number of competing programs in development. Maintain HOLD." (11/1/2017)
- 4. Wells Fargo & Co analysts commented, "an increased risk of serious liver injury and death." The letter resulted in a 25 percent selloff in Intercept's stock on Thursday, and some Wall Street analyst's felt it prudent to take action.Wells Fargo's Jim Birchenough downgraded Intercept's stock rating from Overweight to Market Perform with a price target slashed from $265 all the way down to $95 as the letter goes beyond a previous warning.The FDA's letter contains new pieces of information that weren't included in the prior "Dear Healthcare Provider Letter," the analyst highlighted. For example, 19 separate deaths have been identified since Ocaliva's launch in May 2016. The cause of death was worsening primary biliary cholangitis in seven of these cases, cardiovascular disease in one case, with the other cases being unknown.Among the eight cases with a known cause of death, seven of the patients received an incorrect dose, Birchenough continued. In addition, the FDA highlighted 11 cases of serious liver injury, of which six patients were given an incorrect dose resulting in three of the 19 deaths."We believe that serious events in patients with mild or no baseline liver disease, treated with correct doses of OCALIVA, and the recommendation for increased monitoring could dramatically impact OCALIVA adoption in PBC, and introduces a potential overhang on the development for non alcoholic steatohepatitis (NASH), with phase 3 data not expected until early 2019 and potential increased risk of imbalance in serious adverse events (SAE's)," (9/21/2017)
Who are some of Intercept Pharmaceuticals' key competitors?
Some companies that are related to Intercept Pharmaceuticals include Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Loxo Oncology (LOXO), Dr. Reddy's Laboratories (RDY), Taro Pharmaceutical Industries (TARO), United Therapeutics (UTHR), GW Pharmaceuticals (GWPH), FibroGen (FGEN) and Hutchison China MediTech (HCM).
Who are Intercept Pharmaceuticals' key executives?
Intercept Pharmaceuticals' management team includes the folowing people:
- Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 50)
- Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 48)
- Dr. David Shapiro M.D., Ph.D., Chief Medical Officer (Age 64)
- Ms. Lisa Bright B.Sc., Pres of International (Age 50)
- Mr. Jerome B. Durso, Chief Operating Officer (Age 50)
Has Intercept Pharmaceuticals been receiving favorable news coverage?
Media headlines about ICPT stock have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Intercept Pharmaceuticals earned a coverage optimism score of 0.10 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.73 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Intercept Pharmaceuticals' major shareholders?
Intercept Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include GENEXTRA S.P.A. (23.30%), Senvest Management LLC (3.89%), BB Biotech AG (1.84%), Altrinsic Global Advisors LLC (1.27%), Elk Creek Partners LLC (1.18%) and Melqart Asset Management UK Ltd (1.01%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, Daniel G Welch, David Shapiro, Francesco Micheli, Keith Michael Gottesdiener, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Institutional Ownership Trends for Intercept Pharmaceuticals.
Which institutional investors are selling Intercept Pharmaceuticals stock?
ICPT stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, A.R.T. Advisors LLC, Guggenheim Capital LLC, Pinnacle Associates Ltd., LPL Financial LLC, BNP Paribas Arbitrage SA, Teacher Retirement System of Texas and State Board of Administration of Florida Retirement System. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Daniel G Welch, David Shapiro, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Insider Buying and Selling for Intercept Pharmaceuticals.
Which institutional investors are buying Intercept Pharmaceuticals stock?
ICPT stock was bought by a variety of institutional investors in the last quarter, including Elk Creek Partners LLC, Point72 Asset Management L.P., Senvest Management LLC, Millennium Management LLC, Melqart Asset Management UK Ltd, Scopia Capital Management LP, Altrinsic Global Advisors LLC and BB Biotech AG. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Francesco Micheli, Keith Michael Gottesdiener and Mark Pruzanski. View Insider Buying and Selling for Intercept Pharmaceuticals.
How do I buy shares of Intercept Pharmaceuticals?
Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intercept Pharmaceuticals' stock price today?
One share of ICPT stock can currently be purchased for approximately $71.07.
How big of a company is Intercept Pharmaceuticals?
Intercept Pharmaceuticals has a market capitalization of $2.06 billion and generates $130.96 million in revenue each year. The biopharmaceutical company earns $-360,360,000.00 in net income (profit) each year or ($14.38) on an earnings per share basis. Intercept Pharmaceuticals employs 507 workers across the globe.
How can I contact Intercept Pharmaceuticals?
Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]
MarketBeat Community Rating for Intercept Pharmaceuticals (ICPT)
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Intercept Pharmaceuticals (NASDAQ:ICPT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
21 Wall Street analysts have issued ratings and price targets for Intercept Pharmaceuticals in the last 12 months. Their average twelve-month price target is $124.4737, suggesting that the stock has a possible upside of 75.14%. The high price target for ICPT is $253.00 and the low price target for ICPT is $50.00. There are currently 3 sell ratings, 8 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.33 | 2.33 | 2.33 | 2.33 |
| Ratings Breakdown: | 3 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 3 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 3 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
10 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $124.4737 | $128.5263 | $128.3684 | $143.5263 |
| Price Target Upside: | 75.14% upside | 73.45% upside | 129.15% upside | 136.34% upside |
Intercept Pharmaceuticals (NASDAQ:ICPT) Consensus Price Target History
Intercept Pharmaceuticals (NASDAQ:ICPT) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Intercept Pharmaceuticals (NASDAQ:ICPT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Intercept Pharmaceuticals (NASDAQ ICPT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.90%
Institutional Ownership Percentage: 66.19%
Intercept Pharmaceuticals (NASDAQ ICPT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/9/2018 | Francesco Micheli | Major Shareholder | Buy | 390,625 | $64.00 | $25,000,000.00 | |  |
| 4/9/2018 | Keith Michael Gottesdiener | Director | Buy | 1,171 | $64.00 | $74,944.00 | 5,001 | |
| 4/9/2018 | Mark Pruzanski | CEO | Buy | 7,812 | $64.00 | $499,968.00 | 11,642 | |
| 10/2/2017 | David Shapiro | CMO | Sell | 349 | $58.90 | $20,556.10 | | |
| 10/2/2017 | Mark Pruzanski | CEO | Sell | 1,532 | $58.87 | $90,188.84 | | |
| 10/2/2017 | Rachel Mcminn | Insider | Sell | 283 | $58.89 | $16,665.87 | | |
| 10/2/2017 | Richard J Kim | SVP | Sell | 48 | $58.10 | $2,788.80 | | |
| 10/2/2017 | Sandip Kapadia | CFO | Sell | 354 | $58.83 | $20,825.82 | | |
| 9/1/2017 | David Shapiro | CMO | Sell | 1,250 | $117.43 | $146,787.50 | 45,812 | |
| 8/25/2017 | Lisa Bright | Insider | Sell | 253 | $111.31 | $28,161.43 | 23,324 | |
| 8/2/2017 | Lisa Bright | Insider | Sell | 142 | $110.29 | $15,661.18 | 23,477 | |
| 8/1/2017 | David Shapiro | CMO | Sell | 1,118 | $119.00 | $133,042.00 | 45,680 | |
| 7/31/2017 | Daniel G Welch | Director | Sell | 602 | $123.93 | $74,605.86 | 3,108 | |
| 7/31/2017 | Rachel Mcminn | Insider | Sell | 130 | $123.12 | $16,005.60 | 17,158 | |
| 7/20/2017 | Daniel G Welch | Director | Sell | 217 | $126.76 | $27,506.92 | 3,710 | |
| 7/14/2017 | Richard J Kim | SVP | Sell | 89 | $128.64 | $11,448.96 | 11,253 | |
| 7/11/2017 | David Shapiro | CMO | Sell | 553 | $124.01 | $68,577.53 | 44,562 | |
| 7/3/2017 | David Shapiro | CMO | Sell | 350 | $121.24 | $42,434.00 | 45,215 | |
| 7/3/2017 | Lisa Bright | Insider | Sell | 394 | $121.33 | $47,804.02 | 23,619 | |
| 7/3/2017 | Mark Pruzanski | CEO | Sell | 1,434 | $121.78 | $174,632.52 | 570,284 | |
| 7/3/2017 | Richard J Kim | SVP | Sell | 50 | $121.69 | $6,084.50 | 11,342 | |
| 7/3/2017 | Sandip Kapadia | CFO | Sell | 1,431 | $121.59 | $173,995.29 | 20,569 | |
| 6/26/2017 | Mark Pruzanski | CEO | Sell | 40,000 | $130.80 | $5,232,000.00 | 611,718 | |
| 6/1/2017 | Lisa Bright | Insider | Sell | 698 | $110.73 | $77,289.54 | 24,711 | |
| 5/25/2017 | Lisa Bright | Insider | Sell | 254 | $117.52 | $29,850.08 | 23,246 | |
| 5/16/2017 | Lisa Bright | Insider | Sell | 113 | $119.74 | $13,530.62 | 23,613 | |
| 5/2/2017 | Lisa Bright | Insider | Sell | 426 | $114.00 | $48,564.00 | 23,804 | |
| 5/1/2017 | David Shapiro | CMO | Sell | 1,117 | $112.18 | $125,305.06 | 46,582 | |
| 5/1/2017 | Rachel Mcminn | Insider | Sell | 114 | $113.12 | $12,895.68 | 17,545 | |
| 4/10/2017 | David Shapiro | CMO | Sell | 558 | $108.51 | $60,548.58 | 45,465 | |
| 4/3/2017 | David Shapiro | CMO | Sell | 346 | $115.00 | $39,790.00 | 46,023 | |
| 4/3/2017 | Lisa Bright | Insider | Sell | 389 | $115.00 | $44,735.00 | 22,925 | |
| 4/3/2017 | Mark Pruzanski | CEO | Sell | 1 | $115.00 | $115.00 | 571,718 | |
| 2/27/2017 | Lisa Bright | Insider | Sell | 254 | $119.48 | $30,347.92 | 21,695 | |
| 1/31/2017 | Lisa Bright | Insider | Sell | 134 | $108.96 | $14,600.64 | 17,383 | |
| 1/9/2017 | David Shapiro | CMO | Sell | 1,565 | $106.01 | $165,905.65 | 40,369 | |
| 1/3/2017 | David Shapiro | CMO | Sell | 988 | $103.92 | $102,672.96 | 41,934 | |
| 1/3/2017 | Mark Pruzanski | CEO | Sell | 2,802 | $103.92 | $291,183.84 | 552,705 | |
| 1/3/2017 | Rachel Mcminn | Insider | Sell | 816 | $103.92 | $84,798.72 | 12,916 | |
| 12/2/2016 | David Shapiro | CMO | Sell | 1,350 | $99.75 | $134,662.50 | 42,922 | |
| 11/25/2016 | Lisa Bright | Insider | Sell | 249 | $113.60 | $28,286.40 | 18,209 | |
| 10/31/2016 | Rachel Mcminn | Insider | Sell | 129 | $123.82 | $15,972.78 | 13,732 | |
| 10/10/2016 | David Shapiro | CMO | Sell | 411 | $153.34 | $63,022.74 | 44,272 | |
| 10/3/2016 | Barbara Gayle Duncan | CAO | Sell | 147 | $163.20 | $23,990.40 | 30,661 | |
| 10/3/2016 | David Shapiro | CMO | Sell | 1,513 | $163.08 | $246,740.04 | 46,196 | |
| 10/3/2016 | Lisa Bright | Insider | Sell | 155 | $163.20 | $25,296.00 | 18,305 | |
| 10/3/2016 | Mark Pruzanski | CEO | Sell | 705 | $163.20 | $115,056.00 | 552,020 | |
| 9/26/2016 | David Shapiro | CMO | Sell | 3,545 | $165.08 | $585,208.60 | 45,732 | |
| 9/20/2016 | Mark Pruzanski | CEO | Sell | 35,000 | $165.00 | $5,775,000.00 | 579,314 | |
| 8/25/2016 | Lisa Bright | Insider | Sell | 246 | $159.00 | $39,114.00 | 18,460 | |
| 8/1/2016 | Rachel Mcminn | Insider | Sell | 125 | $176.57 | $22,071.25 | 13,861 | |
| 7/5/2016 | Barbara Gayle Duncan | CAO | Sell | 146 | $145.11 | $21,186.06 | | |
| 7/5/2016 | David Shapiro | CMO | Sell | 163 | $145.11 | $23,652.93 | | |
| 7/5/2016 | Lisa Bright | Insider | Sell | 155 | $145.11 | $22,492.05 | | |
| 7/5/2016 | Mark Pruzanski | CEO | Sell | 714 | $145.11 | $103,608.54 | | |
| 5/25/2016 | Lisa Bright | Insider | Sell | 251 | $137.50 | $34,512.50 | 18,855 | |
| 5/2/2016 | Rachel Mcminn | Insider | Sell | 130 | $147.49 | $19,173.70 | 14,087 | |
| 4/4/2016 | Barbara Gayle Duncan | CFO | Sell | 144 | $130.76 | $18,829.44 | 30,948 | |
| 4/4/2016 | David Shapiro | CMO | Sell | 165 | $130.76 | $21,575.40 | 48,546 | |
| 4/4/2016 | Lisa Bright | Insider | Sell | 153 | $130.76 | $20,006.28 | 19,106 | |
| 4/4/2016 | Mark Pruzanski | CEO | Sell | 708 | $130.76 | $92,578.08 | 548,248 | |
| 2/25/2016 | Lisa Bright | Insider | Sell | 241 | $115.22 | $27,768.02 | 19,259 | |
| 2/1/2016 | Rachel Mcminn | Insider | Sell | 128 | $103.56 | $13,255.68 | 7,621 | |
| 1/13/2016 | Lisa Bright | insider | Sell | 728 | $125.52 | $91,378.56 | 11,700 | |
| 1/4/2016 | Barbara Gayle Duncan | CFO | Sell | 468 | $145.90 | $68,281.20 | 24,892 | |
| 1/4/2016 | David Shapiro | CMO | Sell | 533 | $145.90 | $77,764.70 | 40,911 | |
| 1/4/2016 | Mark Pruzanski | CEO | Sell | 2,126 | $145.90 | $310,183.40 | 529,556 | |
| 1/4/2016 | Rachel Mcminn | Insider | Sell | 469 | $145.90 | $68,427.10 | 7,749 | |
| 11/25/2015 | Lisa Bright | Insider | Sell | 1,150 | $182.96 | $210,404.00 | 12,428 | |
| 11/16/2015 | David Shapiro | CMO | Sell | 4,264 | $178.53 | $761,251.92 | 28,395 | |
| 11/10/2015 | David Shapiro | CMO | Sell | 3,500 | $204.15 | $714,525.00 | 29,159 | |
| 11/10/2015 | Klaus R. Dr Veitinger | Director | Sell | 1,000 | $198.25 | $198,250.00 | 2,166 | |
| 11/2/2015 | Rachel Mcminn | Insider | Sell | 125 | $160.24 | $20,030.00 | 8,218 | |
| 10/2/2015 | Barbara Gayle Duncan | CFO | Sell | 1,054 | $163.17 | $171,981.18 | 24,062 | |
| 10/2/2015 | David Shapiro | CMO | Sell | 1,140 | $160.12 | $182,536.80 | 29,159 | |
| 9/21/2015 | Nicole Williams | Director | Sell | 973 | $194.82 | $189,559.86 | 962 | |
| 9/15/2015 | David Shapiro | CMO | Sell | 3,500 | $191.28 | $669,480.00 | 23,527 | |
| 8/17/2015 | David Shapiro | CMO | Sell | 4,272 | $209.37 | $894,428.64 | | |
| 7/20/2015 | Nicole Williams | Director | Sell | 973 | $279.01 | $271,476.73 | | |
| 7/10/2015 | Mark Pruzanski | CEO | Sell | 12,500 | $250.00 | $3,125,000.00 | | |
| 7/6/2015 | Luciano Adorini | Insider | Sell | 4,067 | $579.93 | $2,358,575.31 | | |
| 7/1/2015 | Barbara Gayle Duncan | CFO | Sell | 1,000 | $242.10 | $242,100.00 | | |
| 7/1/2015 | David Shapiro | CMO | Sell | 3,781 | $238.66 | $902,373.46 | | |
| 6/22/2015 | Nicole Williams | Director | Sell | 974 | $265.14 | $258,246.36 | | |
| 6/15/2015 | David Shapiro | CMO | Sell | 3,500 | $241.58 | $845,530.00 | | |
| 6/8/2015 | Luciano Adorini | Insider | Sell | 4,000 | $248.40 | $993,600.00 | | |
| 5/11/2015 | Klaus R Dr Veitinger | Director | Sell | 391 | $279.07 | $109,116.37 | | |
| 5/6/2015 | Luciano Adorini | Insider | Sell | 4,000 | $259.97 | $1,039,880.00 | | |
| 4/20/2015 | Nicole Williams | Director | Sell | 974 | $278.50 | $271,259.00 | | |
| 4/6/2015 | Luciano Adorini | Insider | Sell | 4,000 | $269.64 | $1,078,560.00 | | |
| 4/2/2015 | David Shapiro | CMO | Sell | 3,459 | $275.25 | $952,089.75 | | |
| 3/26/2015 | Orbimed Advisors Llc | Director | Sell | 157,200 | $286.75 | $45,077,100.00 | | |
| 3/25/2015 | Orbimed Advisors Llc | Director | Sell | 207,800 | $274.41 | $57,022,398.00 | | |
| 3/24/2015 | Jonathan Silverstein | Director | Sell | 45,600 | $272.00 | $12,403,200.00 | | |
| 3/23/2015 | Jonathan Silverstein | Director | Sell | 159,400 | $275.18 | $43,863,692.00 | | |
| 3/16/2015 | David Shapiro | CMO | Sell | 3,500 | $286.90 | $1,004,150.00 | | |
| 1/12/2015 | Klaus R Dr Veitinger | Director | Sell | 233 | $150.01 | $34,952.33 | | |
| 1/5/2015 | Barbara Gayle Duncan | CFO | Sell | 141 | $176.49 | $24,885.09 | | |
| 1/5/2015 | Daniel Paul Regan | Insider | Sell | 146 | $176.49 | $25,767.54 | | |
| 1/5/2015 | David Shapiro | CMO | Sell | 664 | $172.63 | $114,626.32 | | |
| 1/5/2015 | Mark Pruzanski | CEO | Sell | 461 | $176.49 | $81,361.89 | | |
| 1/2/2015 | Barbara Gayle Duncan | CFO | Sell | 1,000 | $156.40 | $156,400.00 | | |
| 11/17/2014 | David Shapiro | CMO | Sell | 4,790 | $158.82 | $760,747.80 | | |
| 11/12/2014 | Srinivas Akkaraju | Director | Buy | 2,000 | $167.19 | $334,380.00 | | |
| 11/10/2014 | Klaus R Dr Veitinger | Director | Sell | 233 | $175.95 | $40,996.35 | | |
| 11/3/2014 | Mark Pruzanski | CEO | Sell | 10,000 | $259.41 | $2,594,100.00 | | |
| 10/10/2014 | Klaus R Dr Veitinger | Director | Sell | 391 | $223.65 | $87,447.15 | | |
| 10/2/2014 | David Shapiro | CMO | Sell | 5,020 | $231.63 | $1,162,782.60 | | |
| 10/1/2014 | Barbara Gayle Duncan | CFO | Sell | 1,000 | $233.12 | $233,120.00 | | |
| 10/1/2014 | David Shapiro | CMO | Sell | 4,188 | $231.17 | $968,139.96 | | |
| 10/1/2014 | Mark Pruzanski | CEO | Sell | 10,000 | $228.82 | $2,288,200.00 | | |
| 9/15/2014 | David Shapiro | CMO | Sell | 4,000 | $281.19 | $1,124,760.00 | | |
| 9/10/2014 | Klaus R Dr Veitinger | Director | Sell | 391 | $280.50 | $109,675.50 | | |
| 9/2/2014 | Mark Pruzanski | CEO | Sell | 10,000 | $286.49 | $2,864,900.00 | | |
| 8/27/2014 | David Shapiro | CMO | Sell | 10,000 | $293.93 | $2,939,300.00 | | |
| 8/26/2014 | Orbimed Advisors Llc | Director | Sell | 111,258 | $298.06 | $33,161,559.48 | | |
| 8/25/2014 | Jonathan Silverstein | Director | Sell | 50,000 | $295.59 | $14,779,500.00 | | |
| 8/15/2014 | David Shapiro | CMO | Sell | 4,774 | $291.49 | $1,391,573.26 | | |
| 8/12/2014 | Daniel Paul Regan | Insider | Sell | 8,124 | $325.70 | $2,645,986.80 | | |
| 8/12/2014 | Klaus R Dr Veitinger | Director | Sell | 316 | $345.62 | $109,215.92 | | |
| 8/1/2014 | Mark Pruzanski | CEO | Sell | 10,000 | $226.72 | $2,267,200.00 | | |
| 7/10/2014 | Klaus R Dr Veitinger | Director | Sell | 391 | $219.15 | $85,687.65 | | |
| 7/7/2014 | Lorenzo Tallarigo | Director | Sell | 2,000 | $243.06 | $486,120.00 | | |
| 7/2/2014 | David Shapiro | CMO | Sell | 5,036 | $244.73 | $1,232,460.28 | | |
| 7/1/2014 | Mark Pruzanski | CEO | Sell | 10,000 | $250.61 | $2,506,100.00 | | |
| 6/16/2014 | David Shapiro | CMO | Sell | 4,000 | $278.15 | $1,112,600.00 | | |
| 6/2/2014 | Mark Pruzanski | CEO | Sell | 10,000 | $230.60 | $2,306,000.00 | | |
| 5/9/2014 | Lorenzo Tallarigo | Director | Sell | 2,007 | $254.68 | $511,142.76 | | |
| 5/1/2014 | Mark Pruzanski | CEO | Sell | 10,000 | $263.17 | $2,631,700.00 | 470,174 | |
| 4/16/2014 | Mark Pruzanski | CEO | Sell | 10,000 | $242.22 | $2,422,200.00 | 470,174 | |
| 4/14/2014 | Barbara Gayle Duncan | CFO | Sell | 1,154 | $279.00 | $321,966.00 | 13,510 | |
| 4/10/2014 | Lorenzo Tallarigo | Director | Sell | 349,318 | $317.71 | $110,981,821.78 | 1,640 | |
| 4/9/2014 | Orbimed Advisors Llc | Director | Sell | 81,305 | $320.00 | $26,017,600.00 | | |
| 4/7/2014 | Luciano Adorini | Insider | Sell | 2,000 | $283.90 | $567,800.00 | 7,041 | |
| 4/2/2014 | David Shapiro | CMO | Sell | 5,393 | $331.83 | $1,789,559.19 | 13,679 | |
| 3/17/2014 | David Shapiro | CMO | Sell | 4,456 | $437.49 | $1,949,455.44 | 13,124 | |
| 2/14/2014 | Paolo Fundaro | Director | Sell | 7,246 | $375.26 | $2,719,133.96 | 1,655 | |
| 1/16/2014 | Mark Pruzanski | CEO | Sell | 10,000 | $273.68 | $2,736,800.00 | 430,298 | |
| 1/16/2014 | Srinivas Akkaraju | Director | Sell | 3,250 | $267.94 | $870,805.00 | 1,943 | |
| 1/8/2014 | David Shapiro | CMO | Sell | 4,928 | $71.85 | $354,076.80 | 8,663 | |
| 1/7/2014 | Lorenzo Tallarigo | Director | Sell | 1,839 | $67.41 | $123,966.99 | 1,640 | |
| 1/7/2014 | Luciano Adorini | Insider | Sell | 1,634 | $67.41 | $110,147.94 | 6,392 | |
| 12/16/2013 | David Shapiro | CMO | Sell | 5,016 | $62.11 | $311,543.76 | 3,000 | |
| 10/21/2013 | Francesco Micheli | Major Shareholder | Sell | 124,912 | $62.50 | $7,807,000.00 | | |
| 10/21/2013 | Jonathan Silverstein | Director | Sell | 40,088 | $62.50 | $2,505,500.00 | | |
| 10/21/2013 | Luciano Adorini | Insider | Sell | 2,000 | $55.51 | $111,020.00 | | |
| 10/15/2013 | Francesco Micheli | Major Shareholder | Sell | 1,123,415 | $62.50 | $70,213,437.50 | | |
| 10/15/2013 | Orbimed Advisors Llc | Director | Sell | 376,585 | $62.50 | $23,536,562.50 | | |
| 10/2/2013 | David Shapiro | CMO | Sell | 4,392 | $72.80 | $319,737.60 | | |
| 9/20/2013 | Luciano Adorini | Insider | Sell | 2,000 | $61.07 | $122,140.00 | 5,094 | |
| 9/17/2013 | Mark Pruzanski | CEO | Sell | 25,000 | $52.00 | $1,300,000.00 | 402,032 | |
| 9/13/2013 | Mark Pruzanski | CEO | Sell | 12,500 | $49.02 | $612,750.00 | 402,032 | |
| 8/20/2013 | Luciano Adorini | Insider | Sell | 2,000 | $44.18 | $88,360.00 | 5,094 | |
| 8/16/2013 | David Shapiro | CMO | Sell | 5,016 | $49.20 | $246,787.20 | 4,266 | |
| 8/15/2013 | David Shapiro | CMO | Sell | 4,754 | $45.04 | $214,120.16 | 2,532 | |
| 8/12/2013 | Mark Pruzanski | CEO | Sell | 12,500 | $45.98 | $574,750.00 | 402,032 | |
| 8/12/2013 | Paolo Fundaro | Director | Sell | 4,759 | $46.13 | $219,532.67 | 1,330 | |
| 7/22/2013 | Luciano Adorini | Insider | Sell | 2,000 | $49.44 | $98,880.00 | | |
| 7/15/2013 | Mark Pruzanski | CEO | Sell | 25,000 | $50.05 | $1,251,250.00 | | |
| 7/9/2013 | Mark Pruzanski | CEO | Sell | 37,500 | $46.36 | $1,738,500.00 | | |
| 7/8/2013 | Barbara Gayle Duncan | CFO | Sell | 25,000 | $45.39 | $1,134,750.00 | | |
| 7/2/2013 | David Shapiro | CMO | Sell | 4,369 | $43.63 | $190,619.47 | | |
| 6/26/2013 | Mark Pruzanski | CEO | Sell | 12,500 | $40.06 | $500,750.00 | | |
| 6/20/2013 | Luciano Adorini | Insider | Sell | 2,000 | $37.07 | $74,140.00 | | |
| 6/20/2013 | Mark Pruzanski | CEO | Sell | 25,000 | $38.25 | $956,250.00 | | |
| 6/19/2013 | Barbara Gayle Duncan | CFO | Sell | 50,575 | $34.50 | $1,744,837.50 | | |
| 6/17/2013 | David Shapiro | CMO | Sell | 5,016 | $32.72 | $164,123.52 | | |
| 5/28/2013 | Barbara Gayle Duncan | CFO | Sell | 6,225 | $34.50 | $214,762.50 | | |
| 5/20/2013 | Barbara Gayle Duncan | CFO | Sell | 28,200 | $34.50 | $972,900.00 | | |
| 5/16/2013 | David Shapiro | CMO | Sell | 5,016 | $31.31 | $157,050.96 | | |
| 4/9/2013 | David Shapiro | CMO | Sell | 3,750 | $34.41 | $129,037.50 | | |
| 10/16/2012 | Jonathan Silverstein | Director | Buy | 333,334 | $15.00 | $5,000,010.00 | | |
(Data available from 1/1/2013 forward)
Intercept Pharmaceuticals (NASDAQ ICPT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Intercept Pharmaceuticals (ICPT) Could See Upside on Upcoming Competitor NASH Data - RBC
www.streetinsider.com - May 24 at 8:41 AM |
 | FY2018 EPS Estimates for Intercept Pharmaceuticals (ICPT) Lifted by Cantor Fitzgerald
www.americanbankingnews.com - May 24 at 8:36 AM |
| Intercept Pharmaceuticals (ICPT) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 20 at 8:14 AM |
 | Notable Friday Option Activity: ICPT, JNJ, CELG
www.nasdaq.com - May 18 at 5:26 PM |
| Intercept Pharmaceuticals' (ICPT) "Buy" Rating Reiterated at Wedbush
www.americanbankingnews.com - May 18 at 4:45 PM |
 | Report: Developing Opportunities within AG Mortgage Investment Trust, Associated Banc-Corp, Reata Pharmaceuticals, Nathan's Famous, United Fire Group, and Intercept Pharmaceuticals — Future Expectations, Projections Moving into 2018
finance.yahoo.com - May 18 at 9:15 AM |
| Intercept Pharmaceuticals Forecasted to Post Q2 2018 Earnings of ($2.71) Per Share (ICPT)
www.americanbankingnews.com - May 18 at 7:30 AM |
| ValuEngine Downgrades Intercept Pharmaceuticals (ICPT) to Strong Sell
www.americanbankingnews.com - May 17 at 4:41 PM |
| Wedbush Weighs in on Intercept Pharmaceuticals' Q1 2019 Earnings (ICPT)
www.americanbankingnews.com - May 17 at 8:48 AM |
| Analysts Anticipate Intercept Pharmaceuticals (ICPT) Will Post Quarterly Sales of $39.42 Million
www.americanbankingnews.com - May 15 at 4:58 AM |
| Seaport Global Securities Weighs in on Intercept Pharmaceuticals' Q2 2018 Earnings (ICPT)
www.americanbankingnews.com - May 14 at 2:18 AM |
| Intercept Pharmaceuticals (ICPT) Expected to Announce Earnings of -$3.06 Per Share
www.americanbankingnews.com - May 13 at 1:20 AM |
| Intercept Pharmaceuticals (ICPT) Earns Buy Rating from Wedbush
www.americanbankingnews.com - May 11 at 7:05 PM |
| Jefferies Group Comments on Intercept Pharmaceuticals' Q2 2018 Earnings (ICPT)
www.americanbankingnews.com - May 11 at 9:41 AM |
| Intercept Pharmaceuticals Forecasted to Post Q2 2018 Earnings of ($2.75) Per Share (ICPT)
www.americanbankingnews.com - May 11 at 9:41 AM |
| Oppenheimer Weighs in on Intercept Pharmaceuticals' Q2 2018 Earnings (ICPT)
www.americanbankingnews.com - May 11 at 9:39 AM |
| Analysts Anticipate 14% Upside For FXH
www.nasdaq.com - May 10 at 5:26 PM |
 | Intercept Pharmaceuticals Announces First Quarter 2018 Financial Results, Issues 2018 Ocaliva Net Sales Guidance ...
globenewswire.com - May 10 at 5:26 PM |
 | BRIEF-Intercept Pharmaceuticals Says 2018 Worldwide Ocaliva Net Sales Currently Expected To Be Between $170 ...
www.reuters.com - May 10 at 5:26 PM |
| Edited Transcript of ICPT earnings conference call or presentation 8-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 8:52 AM |
| Intercept Pharmaceuticals (ICPT) Receives Buy Rating from Cowen
www.americanbankingnews.com - May 9 at 9:42 PM |
| Intercept Pharmaceuticals (ICPT) Receives Hold Rating from Oppenheimer
www.americanbankingnews.com - May 9 at 12:08 PM |
 | Intercept Pharmaceuticals (ICPT) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:11 PM |
| Cantor Fitzgerald Reaffirms "Hold" Rating for Intercept Pharmaceuticals (ICPT)
www.americanbankingnews.com - May 8 at 2:49 PM |
| Intercept Pharmaceuticals (ICPT) Posts Earnings Results, Beats Expectations By $0.15 EPS
www.americanbankingnews.com - May 8 at 2:23 PM |
| Intercept: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 8:44 AM |
| Intercept Pharmaceuticals to Post Q1 2018 Earnings of ($3.42) Per Share, Oppenheimer Forecasts (ICPT)
www.americanbankingnews.com - May 7 at 1:16 AM |
| Intercept to Announce First Quarter 2018 Financial Results on May 8, 2018 and Present at Upcoming Investor Conferences
finance.yahoo.com - May 2 at 8:44 AM |
| What's in Store for Intercept (ICPT) This Earnings Season?
finance.yahoo.com - May 1 at 8:50 AM |
| What's in Store for Intercept (ICPT) This Earnings Season?
finance.yahoo.com - May 1 at 8:50 AM |
| BRIEF-Intercept Pharmaceuticals Says Co's Board Increased Size Of Board From Nine Directors To Ten Directors
www.reuters.com - April 28 at 9:00 AM |
| BRIEF-Intercept Pharmaceuticals CEO Mark Pruzanski's FY 2017 Total Compensation Was $6.2 Million
www.reuters.com - April 28 at 9:00 AM |
| Rounds Report: Unlocking Value Of Omeros And Intercept
seekingalpha.com - April 27 at 9:02 AM |
| Intercept Pharmaceuticals (ICPT) Expected to Post Quarterly Sales of $37.79 Million
www.americanbankingnews.com - April 27 at 2:58 AM |
| Intercept Pharmaceuticals (ICPT) Expected to Announce Earnings of -$3.40 Per Share
www.americanbankingnews.com - April 25 at 1:24 PM |
| Intercept Pharmaceuticals (ICPT) to Release Earnings on Wednesday
www.americanbankingnews.com - April 25 at 3:52 AM |
| Intercept Pharma (ICPT) Announces Nancy Miller-Rich to Board
www.streetinsider.com - April 24 at 5:16 PM |
| Intercept Pharmaceuticals Appoints Nancy Miller-Rich to Its Board of Directors
finance.yahoo.com - April 24 at 8:42 AM |
| Research Analysts Set Expectations for Intercept Pharmaceuticals Inc's Q1 2018 Earnings (ICPT)
www.americanbankingnews.com - April 19 at 7:08 AM |
| BidaskClub Upgrades Intercept Pharmaceuticals (ICPT) to "Buy"
www.americanbankingnews.com - April 18 at 10:06 AM |
| Jefferies Group Weighs in on Intercept Pharmaceuticals Inc's Q1 2018 Earnings (ICPT)
www.americanbankingnews.com - April 18 at 7:54 AM |
| Intercept Pharmaceuticals (ICPT) Given New $256.00 Price Target at Wedbush
www.americanbankingnews.com - April 17 at 8:49 AM |
 | Intercept Reports Phase III Sub-Study Liver Biopsy Data
www.zacks.com - April 16 at 5:01 PM |
| Intercept Pharmaceuticals (ICPT) Receives Hold Rating from Laidlaw
www.americanbankingnews.com - April 14 at 2:30 PM |
| 11 of 13 patients improved or maintained histological fibrosis stage after three years of treatment with obeticholic acid (OCA)
globenewswire.com - April 13 at 8:55 AM |
| Intercept Pharma's obeticholic acid shows positive effect on fibrosis and cirrhosis in late-stage study; shares up 3% premarket
seekingalpha.com - April 13 at 8:55 AM |
| CymaBay Therapeutics Pushes Itself To The Next Stage Against Rare Liver Disease
seekingalpha.com - April 12 at 9:21 AM |
| Analysts Anticipate Intercept Pharmaceuticals Inc (ICPT) Will Announce Quarterly Sales of $38.55 Million
www.americanbankingnews.com - April 10 at 2:56 AM |
| Intercept Pharmaceuticals Inc (ICPT) CEO Acquires $499,968.00 in Stock
www.americanbankingnews.com - April 9 at 10:26 PM |
| Intercept Pharmaceuticals Inc (ICPT) Director Keith Michael Gottesdiener Acquires 1,171 Shares
www.americanbankingnews.com - April 9 at 10:26 PM |
Intercept Pharmaceuticals (NASDAQ:ICPT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Intercept Pharmaceuticals (NASDAQ:ICPT) Income Statement, Balance Sheet and Cash Flow Statement
Intercept Pharmaceuticals (NASDAQ ICPT) Stock Chart for Saturday, May, 26, 2018
Loading chart…
